Anagenics (AN1) Stock Price, News & Analysis

Company Overview

Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$3.69 million
• P/E Ratio: N/A
• Dividend Yield: 0.88%
• Price Target: N/A
• Consensus Rating: N/A

AN1 Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Anagenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anagenics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX) and First Trust United Kingdom AlphaDEX Fund (FKU).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Consumer Defensive
• Industry: Household & Personal Products
• Sub-Industry: N/A
• Current Symbol: ASX:AN1
• CIK: N/A
• Web: www.anagenics.com
• Phone: 61 2 9221 6830
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$7.28 million
• Net Margins: -60.56%
• Pretax Margin: N/A
• Return on Equity: -148.47%
• Return on Assets: -27.82%

Debt

• Debt-to-Equity Ratio: 28.51
• Current Ratio: 1.21
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: A$10.80 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 461,320,000
• Free Float: N/A
• Market Cap: A$3.69 million
• Optionable: Not Optionable
• Beta: -1.03